Bluebird Bio Announces EU Conditional Marketing Authorization For ZYNTEGLO Gene Therapy For Patients 12 Years And Older With Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
Benzinga Newsdesk